Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy
Authors:
- 1 November 2006
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 12 (6) , 579-590
Abstract
This article reviews the epidemiology of inhibitor formation in patients receiving recombinant factor VIII (rFVIII) replacement therapy for haemophilia A. Data from pivotal trial programmes, post-marketing surveillance studies, and pharmacovigilance studies for all available rFVIII products were reviewed. To date, no comparative studies have been performed, and in the non-comparative studies, there were differences in the patient population enrolled and study design (including the number of patient exposure days). In the absence of comparative clinical trials, it is not possible to make comparisons between inhibitor data for the various rFVIII products. This review of the epidemiological data shows that across the pivotal trial programmes for rFVIII products, the observed incidence of inhibitors was in the range of 15-32% in previously untreated patients (PUPs) and 0.9-2.9% in previously treated patients (PTPs). High-titre inhibitors (peak >5 BU) were detected in 10-16% of PUPs and 0-2.3% of PTPs. Several initiatives proposed to help standardize collection and interpretation of inhibitor data for patients receiving rFVIII treatment are described. Such standardization would help to clarify the epidemiology of inhibitor formation across FVIII treatments.Keywords
This publication has 38 references indexed in Scilit:
- The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an updateHaemophilia, 2005
- Inhibitors in congenital coagulation disordersBritish Journal of Haematology, 2004
- Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1Haemophilia, 2004
- Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IXJournal of Thrombosis and Haemostasis, 2004
- Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigationJournal of Thrombosis and Haemostasis, 2004
- Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patientsSeminars in Hematology, 2001
- Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patientsSeminars in Hematology, 2001
- Human recombinant DNA‐derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5‐year study of home therapyHaemophilia, 1999
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958